[Clinical evaluation of sulbactam/cefoperazone for severe infections associated with hematological disorders].
The combination therapy of sulbactam/cefoperazone (SBT/CPZ) and piperacillin (PIPC) was evaluated in 49 patients with severe infections associated with hematological disorders. Clinical responses in 43 evaluable patients out of the 49 patients were excellent in 12, good in 18, thus, overall efficacy rate was 69.8% (excellent plus good). Efficacy rates of this combination therapy were 60% (3/5) for sepsis, 75% (21/28) for suspected sepsis, and 50% (4/8) for pneumonia. The efficacy rate was 71.4% (10/14) in patients with neutrophil counts less than 200/microliters; this combination therapy was highly effective even in the neutropenic patients. Transient increases in hepatic function test values were observed in 2 patients, but no other side effects were observed during the combination therapy. From these observations it appears that the combination therapy of SBT/CPZ and PIPC is a very useful empiric therapy for severe infections associated with hematological diseases.
Toyama
K
K
First Department of Internal Medicine, Tokyo Medical College.
Torii
Y
Y
Aoki
I
I
Kikuchi
M
M
Wakasugi
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002438:Cefoperazone / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D010878:Piperacillin / Q000627:therapeutic use*; D011014:Pneumonia / Q000150:complications / Q000188:drug therapy*; D018805:Sepsis / Q000150:complications / Q000188:drug therapy*; D013407:Sulbactam / Q000627:therapeutic use*
D002438:Cefoperazone; D013407:Sulbactam; D010878:Piperacillin